Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases
- PMID: 29389236
- DOI: 10.1200/JCO.2017.77.0115
Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases
Comment in
-
Reply to L. Kennedy et al.J Clin Oncol. 2018 Apr 1;36(10):1052-1053. doi: 10.1200/JCO.2017.77.2749. Epub 2018 Feb 1. J Clin Oncol. 2018. PMID: 29389230 No abstract available.
Comment on
-
Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).J Clin Oncol. 2017 Dec 10;35(35):3949-3955. doi: 10.1200/JCO.2017.73.7437. Epub 2017 Oct 12. J Clin Oncol. 2017. PMID: 29023215 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical